Alaunos Therapeutics Inc ((TCRT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alaunos Therapeutics Inc (TCRT) has completed a clinical study titled ‘Evaluation of Ad-RTS-hIL-12 + Veledimex in Combination With Nivolumab in Subjects With Recurrent or Progressive Glioblastoma.’ The study aimed to assess the safety and tolerability of a novel combination therapy for glioblastoma, a challenging brain cancer. This research is significant as it explores innovative immunotherapy approaches to enhance the body’s ability to fight tumor cells.
The study tested the experimental combination of Ad-RTS-hIL-12, a biological agent, with veledimex, an oral drug, and nivolumab, an antibody. This combination is designed to boost the immune system’s response to glioblastoma by enhancing IL-12 effects and improving immune detection of cancer cells.
The study was interventional, with a single-group assignment and no masking, focusing on treatment as its primary purpose. This straightforward design allowed for direct assessment of the treatment’s effects on participants.
The study began on June 18, 2018, with primary completion and results first submitted by March 9, 2025. The latest update was submitted on August 10, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for data analysis and reporting.
This update could influence Alaunos Therapeutics’ stock performance by showcasing its commitment to advancing cancer treatment. Positive results may boost investor confidence, while the competitive landscape in glioblastoma treatment remains intense, with other companies also pursuing similar innovations.
The study is completed, and further details are available on the ClinicalTrials portal.